通过HR-pQCT揭示的CTLA4-Ig在类风湿性关节炎中对骨质侵蚀和骨微架构的优选作用
Naoki Iwamoto1, Ko Chiba2, Shuntaro Sato3
1Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. naoki-iwa@nagasaki-u.ac.jp.
Scientific reports
|November 12, 2024
概括
在类风湿性关节炎 (RA) 患者中,阿巴塞普治疗预防了骨质侵蚀的进展和微观结构的恶化,与传统合成修饰疾病的抗风湿药物 (csDMARDs) 相比. 这表明,阿巴塔塞普特在RA中为骨健康提供了双重益处.
科学领域:
- 类风湿病学 类风湿病学
- 骨生物学 骨生物学 骨生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类风湿性关节炎 (RA) 的特点是关节炎和骨质侵蚀.
- 了解疾病修饰性抗风湿药物 (DMARDs) 对骨结构的影响对于 RA 管理至关重要.
- 高分辨率的外围定量计算断层扫描 (HR-pQCT) 能够对骨微架构进行详细的评估.
研究的目的:
- 为了研究阿巴塔塞普特对 RA 患者骨结构的影响.
- 为了比较与 abatacept 和常规合成DMARDs (csDMARDs) 治疗的患者的骨变化.
- 评估治疗对12个月内骨质侵蚀和微观架构的影响.
主要方法:
- 对RA患者进行前性,非随机化研究,开始服用阿巴cept或csDMARDs.
- 在基线,6个月和12个月时HR-pQCT评估甲手腕头部.
- 肌肉骨超声波和MRI用于评估突炎.
主要成果:
- 与csDMARDs组相比,Abatacept组的侵蚀体积,深度和宽度在数值上变化较小.
- 在12个月的时间里,在阿巴cept组 (1) 与csDMARDs组 (5) 之间,发生的新骨质侵蚀较少.
- 阿巴切保留了骨微型结构,防止了在6个月后在csDMARDs组中观察到的恶化.
结论:
- 在RA患者中,阿巴塞普特有效地预防了骨质侵蚀的进展,包括新的发生.
- 与csDMARDs相比,阿巴切证明了骨微架构的优越保存,独立于突炎.
- 阿巴切在抑制骨质侵蚀和防止RA微型结构恶化方面具有显著的益处.
相关概念视频
01:31Osteoclasts in Bone Remodeling
2.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.8K
01:40Bone Remodeling
38.2K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.2K